Molecule News and Research

RSS

Discovery of key decision-point at which cells with broken DNA repair themselves or die

When cells undergo potentially catastrophic damage, for example as a result of exposure to ionizing radiation, they must make a decision: either to fix the damage or program themselves for death, a process called apoptosis.

12 Apr 2009

Researchers explain process by which cells 'hide' potentially dangerous DNA segments

The DNA in the 23 pairs of chromosomes in each of the billions of cells of the human body is so tightly packed that it would measure six feet in length if stretched end to end.

12 Apr 2009

Researchers reveal how immune cells can be harnessed to target melanoma

Researchers at the Babraham Institute and the University of Catanzaro "Magna Graecia", Italy, co-ordinating an international network of scientists and clinicians from Europe, the USA and Japan, have identified new mechanisms through which the immune system recognises and responds to tumours like melanomas.

12 Apr 2009

For cancer cells, genetics alone is poor indicator for drug response

In certain respects, cells are less like machines and more like people.

12 Apr 2009

Serentis begins trial with first-in-class SRD441 for eczema

Serentis, a privately owned biopharmaceutical company, announced that it has commenced patient recruitment in a Phase II clinical trial for atopic dermatitis (AD), a type of eczema.

9 Apr 2009

New common pathway in neurodegenerative disease is a possible door to a point of no return

A just-out study suggests that what keeps chronic nervous system diseases such as Alzheimer's, Huntington's and ALS going - until they overcome the internal protective mechanisms a body can throw at them - may largely come down to poor conversational skills.

9 Apr 2009

Experimental drug lowers PSA levels

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels – a marker for tumor growth – in men with advanced prostate cancer for whom traditional treatment options have failed.

9 Apr 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

8 Apr 2009

Transplantation immunity breakthrough

Australian scientists have made a discovery that may one day remove the need for a lifetime of toxic immunosuppressive drugs after organ transplants.

8 Apr 2009

New nanostructured biosensors

Research and industry are increasingly exploiting the potential of aptamers.

8 Apr 2009

Breakthrough in transplant medicine

Australian scientists have made a breakthrough in transplantation immunity by finding a way of stopping the immune system from rejecting transplanted organs.

8 Apr 2009

New type of probe enables visualization of single ribonucleic acid

Biomedical engineers have developed a new type of probe that allows them to visualize single ribonucleic acid (RNA) molecules within live cells more easily than existing methods.

6 Apr 2009

Helicos BioSciences releases transcriptome sequencing datasets as open access

Helicos BioSciences has announced the release of transcriptome sequencing (RNA-Seq) datasets on the HeliSphere Technology Center, the company's open access Web site for sharing Helicos datasets and bioinformatics software tools.

6 Apr 2009

Frogs reveal clues about the effects of alcohol during development

Fetal alcohol spectrum disorder (FASD) and Fetal alcohol syndrome (FAS) cause malformations in babies, including facial defects, short stature, and mental and behavioral abnormalities.

6 Apr 2009

2,516 potential biomarkers of pancreatic cancer

A cancer scientist from Johns Hopkins has convinced an international group of colleagues to delay their race to find new cancer biomarkers and instead begin a 7,000-hour slog through a compendium of 50,000 scientific articles already published to assemble, decode and analyze the molecules that might herald the furtive presence of pancreatic cancer.

6 Apr 2009

Researcher tackles deadly brain tumors

Natalie Ciaccio, a fourth-year graduate student researcher in the Department of Pharmaceutical Chemistry at the University of Kansas, is investigating what might be an ideal target for anti-cancer drug therapy, and she is focusing her work on brain tumors specifically.

6 Apr 2009

Pre-cancer screening with urine samples

Dr. Yinfa Ma has developed a method for pre-cancer screening that uses urine samples for detection.

6 Apr 2009

Monoclonal antibody cancer therapy

The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects.

6 Apr 2009

Molecule called miR-29b could be a potent treatment for acute myeloid leukemia

A new study by Ohio State University cancer researchers shows that boosting the level of a molecule called miR-29b in acute myeloid leukemia (AML) cells can reverse gene changes that trap the cells in an immature, fast growing state of development.

5 Apr 2009

FDA clears Cellectar's IND application for drug candidate

Cellectar, Inc., a privately held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its (131)I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.

2 Apr 2009